Results of a randomized, double-blind, placebo-controlled clinical trial evaluating omega-3 fatty acid supplementation in patients with bipolar disorder (BD) were recently published in the Journal of Human Nutrition and Dietetics. Sixty men with BD were randomized to receive either 2 g/day of omega-3 fatty acids or placebo for 8 weeks. Researchers assessed depressive symptoms using the Hamilton Depression Rating Scale and measured serum concentrations of brain-derived neurotrophic factor (BDNF), a key regulator of neuroplasticity and neuronal resilience.
Compared with baseline and placebo, omega-3 supplementation produced significant improvements in biological and clinical outcomes. Serum BDNF concentrations increased by approximately 68%, rising from 0.449 ± 0.110 ng/mL to 0.756 ± 0.160 ng/mL, while Hamilton Depression Rating Scale scores decreased from 40.13 ± 9.51 to 22.40 ± 7.49. These findings suggest omega-3 supplementation may improve depressive symptoms and support biological pathways involved in neuroplasticity.
The results are consistent with a growing body of evidence suggesting omega-3 fatty acids may be particularly beneficial for bipolar depression. Previous meta-analyses have reported improvements in bipolar depression with little effect on mania, while more recent clinical research suggests omega-3 supplementation may help reduce depressive relapse risk in individuals with stable BD. A 2025 narrative review similarly concluded that omega-3s show promise as an adjunctive strategy for managing bipolar disorder symptoms, although larger and longer-term trials are still needed.
The observed increase in BDNF may help explain these clinical effects. Reduced neuroplasticity, systemic inflammation, and neuroinflammation are increasingly recognized as factors involved in the pathophysiology of depression. BDNF supports neuroplasticity, while omega-3 fatty acids influence inflammatory and neuroinflammatory pathways linked to mood regulation. This framework is supported by evidence demonstrating antidepressant effects of omega-3 supplementation, particularly in individuals with major depressive disorder and in populations presenting with depressive symptoms below diagnostic threshold.
Overall, this study adds to the growing evidence supporting omega-3 fatty acids as an adjunctive strategy for bipolar depression. The findings align with broader research suggesting that nutritional factors may influence biological pathways involved in mood regulation and resilience. While larger and longer-term studies are needed, current evidence suggests omega-3 supplementation may provide meaningful support as part of a comprehensive approach.